Two months after Sanofi completed construction in France of its innovative Modulus vaccine and biologics plant—which can be ...

Before Exelexis’ Cabometyx can pass muster with the FDA in its hopeful neuroendocrine tumors indication next April, it will ...

Sac-TMT, also known as SKB264 or MK-2870, represents the first asset in Kelun’s multitarget, multibillion-dollar ADC ...

Once a controversial European depression treatment that never made it to the U.S. | The treatment, which was once a Pfizer ...